Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

[powerpress]

Dr. Greg Riely from Memorial Sloan-Kettering notes how he feels molecular marker results for patients with earlier stage lung cancer can potentially be valuable.

[powerpress]

Dr. William Pao describes how the developers of MyCancerGenome.org envision the website resource being used to help cancer patients, both now and in the future.

[powerpress]

Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.

 [powerpress]

The next live webinar to be done through the partnership of GRACE and LUNGevity Foundation will be on the timely subject of using molecular features of a resected non-small cell lung cancer in order to better understand the probability of the cancer recurring. This will be on November 14th, 7 PM Eastern/4 PM Pacific, and will hope to answer the question, "Could these molecular features improve upon current staging efforts to help us refine our recommendations of which patients should receive post-operative chemotherapy in order to reduce the chance of recurrence?"

Here's part 5 of our Santa Monica program on Molecular Markers in Advanced NSCLC, closing in on the end of the activity.  In this podcast, my friend Dr.

Here's the next installment of the panel discussion on molecular markers from the webinar in Santa Monica with Drs. Charlie Rudin, Alice Shaw, David Spigel, and Glen Goss.  We continued our animated discussion on the promise as well as the pitfalls of broadening the use of molecular markers in routine practice of managing patients with advanced NSCLC.

I'm happy to bring you now the second part of the Santa Monica webinar, developed with the LUNGevity Foundation, on "Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?", in which I was joined by Drs.

This is the first of a series of podcasts from the two hour special webinar we did in partnership with the LUNGevity Foundation at the Santa Monica "Targeted Therapies in Lung Cancer" meeting several weeks ago.  There, I was privileged to be joined by four excellent guest faculty members -- Dr.